Thus, key factors that facilitate a coordinated CD8+ T cell and CD20+ B cell response should be defined, and immunotherapies should be designed to enhance not only CD8+ T cells but also CD20+ B cells in the fight against cancer [39]. The gene discussed is CD8A; the disease is cancer.